The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by MURKO, A.
* Articles by BLACK, D. W.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by MURKO, A.
* Articles by BLACK, D. W.
Related Collections
* Schizophrenia Spectrum Disorders
* Other Neuroleptics
Am J Psychiatry 159:494, March 2002
© 2002 American Psychiatric Association


Letter to the Editor

Clozapine and Pericarditis With Pericardial Effusion

AIDA MURKO, M.D., SARAH CLARKE, P.A.C., and DONALD W. BLACK, M.D.
Iowa City, Iowa

To the Editor: We report the case of a patient receiving clozapine who developed pericarditis with pericardial effusion, which resolved when the drug was discontinued.

Mr. A, a 43-year-old unmarried white man with chronic paranoid schizophrenia that had been stablized with clozapine for 7 years, developed pericardial effusion. More than 1 liter of fluid was removed by means of pericardiocentesis. The fluid gradually reaccumulated, as documented by serial ECGs. Because the treating psychiatrist and cardiologist considered clozapine possibly responsiblefor the effusion, a decision was made to substitute ziprasidone; when a therapeutic dose was reached, the clozapine (775 mg/day) would be slowly tapered and discontinued.

Three weeks later Mr. A came to our hospital emergency treatment center with shortness of breath and chest pain that had lasted for several weeks, along with a 15-lb weight gain. His medications included750 mg/day of clozapine, 160 mg/day of ziprasidone, 240 mg/day of furosemide, and 60 mg/day of paroxetine; paroxetine had been taken for the past 18 months for depressive symptoms. An ECG revealed a sinus rhythm with a rate of 115 bpm and nonspecific T-wave abnormalities. A chest X-ray revealed a stable cardiomegaly.

A physical examination showed a morbidly obese man in no acute distress. His blood pressure was 130/70 mm Hg. His rate of respiration was 20 breaths per minute at rest, and his pulse was 110–120 bpm. His heart sounds were distant, but no rub was present. His lungs were clear to auscultation and percussion. An examination of his extremities revealed 1–2+ pitting edema bilaterally. An ECG showed considerable pericardial fluid, which was suggestive of cardiac tamponade. Mr. A was admitted for a second pericardiocentesis, and 1.2 liters of serosanguineous fluid was withdrawn. The results of fluid analysis were unremarkable. At this point, clozapine was abruptly discontinued. At a 3-month follow-up, there was no reaccumulation of pericardial fluid.

Pericarditis may result from a transmural myocardial infarction, metastatic malignancies, uremia, collagen vascular diseases, radiation, or viral, bacterial, protozoal, or fungal infections. Drugs known to cause pericarditis include procainamide, hydralazine, and isoniazid. The inflammation caused by acute pericarditis often produces exudation of fluid into the pericardial space. Pericardial tamponade develops when fluid accumulates rapidly or the amount of fluid becomes so large that it compresses the heart and presents a life-threatening situation.

We are aware of two reported cases of pericarditis induced by clozapine (1, 2). In each instance, the pericardial effusion developed soon after initiation of treatment and resolved after drug discontinuation. In the first report (1), the pericardial effusion redeveloped when the patient was rechallenged with clozapine. In our patient, the pericardial effusion developed after he had been taking clozapine for 7 years. Of the many possible causes for a pericardial effusion, all were ruled out, with the possible exception of viral infection. The fact that pericardial fluid reaccumulated shortly after the first pericardiocentesis, while Mr. A continued taking clozapine, also suggests the possibility of clozapine-induced pericardial effusion. Because pericardial tamponade can be life threatening, it may be prudent to discontinue clozapine if a patient develops pericardial effusion.

References

  1. Daly JM, Goldberg RJ, Braman SS: Polyserositis associated with clozapine treatment (letter). Am J Psychiatry 1992; 149:1274-1275
  2. Catalano G, Catalano MC, Frankel Wetter RL: Clozapine induced polyserositis. Clin Neuropharmacol 1997; 20:352-356[Medline]




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by MURKO, A.
* Articles by BLACK, D. W.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by MURKO, A.
* Articles by BLACK, D. W.
Related Collections
* Schizophrenia Spectrum Disorders
* Other Neuroleptics


Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org